

**GULF MEDICAL PROJECTS COMPANY**  
**PUBLIC SHAREHOLDING COMPANY**

**CONDENSED CONSOLIDATED INTERIM  
FINANCIAL STATEMENTS FOR THE  
SIX MONTHS PERIOD ENDED  
30 JUNE 2024**

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Condensed consolidated interim financial statements

For the six months period ended 30 June 2024

---

<b>INDEX</b>	<b><u>Page</u></b>	<b><u>Exhibit</u></b>
Review Report on Condensed Consolidated Interim Financial Statements	1	--
Condensed Consolidated Interim Statement of Financial Position	2	A
Condensed Consolidated Interim Statement of Income	3	B
Condensed Consolidated Interim Statement of Comprehensive Income	4	B (Continued)
Condensed Consolidated Interim Statement of Changes in Equity	5	C
Condensed Consolidated Interim Statement of Cash Flows	6	D
Notes to the Condensed Consolidated Interim Financial Statements	7 – 22	--

101380404

**Review Report on Condensed Consolidated Interim  
Financial Statements to the Board of Directors of  
Gulf Medical Projects Company  
Public Shareholding Company**

**Introduction**

We have reviewed the accompanying condensed consolidated interim financial statements of **Gulf Medical Projects Company (PJSC)** (the "Company") and **Its Subsidiary** (together referred to as the "Group") which comprise the condensed consolidated interim statement of financial position as at 30 June 2024 and the condensed consolidated interim statement of income, comprehensive income, changes in equity and cash flows for the six-month period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standard 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this condensed consolidated interim financial statements based on our review.


**Scope of review**

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at 30 June 2024 is not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting'.

**TALAL ABU-GHAZALEH & CO. INTERNATIONAL**



Zaid Ali Musleh  
Licensed Auditor No. 1130

Sharjah, 13 August 2024



**GULF MEDICAL PROJECTS COMPANY (PJSC)**  
Condensed consolidated interim statement of financial position  
As at 30 June 2024

**Exhibit A**

	Note	30 June 2024 (Unaudited) AED '000'	31 December 2023 (Audited) AED '000'
<b>ASSETS</b>			
<b>Non-Current Assets</b>			
Property and equipment	4	699,621	701,900
Intangible assets	5	1,004	960
Right-of-use assets	6	8,571	9,789
Investment properties	7	91,091	91,091
Investments at fair value through other comprehensive income (FVTOCI)	8	204,084	259,053
<b>Total Non-Current Assets</b>		<b>1,004,371</b>	<b>1,062,793</b>
<b>Current Assets</b>			
Inventories	9	16,987	15,160
Due from a related party	10	2,081	2,193
Investments at fair value through profit or loss (FVTPL)	8	35,696	39,406
Accounts receivable and others	11	143,644	117,646
Cash and bank balances	12	127,518	122,785
<b>Total Current Assets</b>		<b>325,926</b>	<b>297,190</b>
<b>TOTAL ASSETS</b>		<b>1,330,297</b>	<b>1,359,983</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>			
Share capital	13	698,916	698,916
Reserves		298,434	298,434
Cumulative change in fair value of investments measured at fair value through other comprehensive income		(45,734)	(49,163)
Retained earnings		113,175	159,078
Net equity attributable to equity holders of the parent company		1,064,791	1,107,265
Non-controlling interest	14	79,880	68,870
<b>Total Equity - Exhibit C</b>		<b>1,144,671</b>	<b>1,176,135</b>
<b>Non-Current Liabilities</b>			
Employees' end of service benefits	15	25,820	25,027
Lease liabilities	16	4,566	5,870
<b>Total Non-Current Liabilities</b>		<b>30,386</b>	<b>30,897</b>
<b>Current Liabilities</b>			
Accounts payable and others	17	148,307	150,706
Lease liabilities	16	3,199	2,245
Income tax liabilities		3,734	--
<b>Total Current Liabilities</b>		<b>155,240</b>	<b>152,951</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>1,330,297</b>	<b>1,359,983</b>

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE  
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**

To the best of our knowledge, the financial information included in these condensed consolidated interim financial statements fairly presents in all material respects the financial condition, result of operation and cash flows of the Group as of, and for, the period presented therein.

These condensed consolidated interim financial statements were approved for issue  
by the Board of Directors on 13 August 2024 and signed on their behalf by :

Sheikh Dr. Faisal Bin Khalid Khalid Al Qasimi  
(Chairman)

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Condensed consolidated interim statement of income

For the six months period ended 30 June 2024 (Unaudited)

## **EXHIBIT B**

	<u>Note</u>	<u>Six months period ended</u>		<u>Three months period ended</u>	
		<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
		AED '000'	AED '000'	AED '000'	AED '000'
Revenues	19	331,210	268,925	164,159	132,973
Cost of revenues	20	(240,018)	(207,999)	(121,146)	(105,753)
Gross profit		91,192	60,926	43,013	27,220
Fair value (loss)/gain of investments at FVTPL					
Other income		(3,710)	2,679	(3,200)	533
General and administrative expenses	21	19,920	16,138	14,864	12,023
Finance costs		(55,959)	(47,337)	(28,740)	(24,130)
		(85)	(109)	(42)	(54)
<b>Profit for the Period before tax</b>		<b>51,358</b>	<b>32,297</b>	<b>25,895</b>	<b>15,592</b>
Income tax expense	26	(3,734)	--	(1,479)	--
<b>Profit for the Period - Exhibit C &amp; D</b>		<b>47,624</b>	<b>32,297</b>	<b>24,416</b>	<b>15,592</b>
<b>Attributable To :</b>					
Equity holders of the parent company		36,614	27,443	19,786	14,228
Non-controlling interest		11,010	4,854	4,630	1,364
<b>Total</b>		<b>47,624</b>	<b>32,297</b>	<b>24,416</b>	<b>15,592</b>
<b>Basic earnings per share (AED)</b>	22	<b>0.052</b>	<b>0.039</b>	<b>0.028</b>	<b>0.020</b>

THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE  
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Condensed consolidated interim statement of comprehensive income  
For the six months period ended 30 June 2024 (Unaudited)

## **EXHIBIT B (CONTINUED)**

	<b>Six months period ended</b>		<b>Three months period ended</b>	
	<b>30 June 2024</b>	<b>30 June 2023</b>	<b>30 June 2024</b>	<b>30 June 2023</b>
	<b>AED '000'</b>	<b>AED '000'</b>	<b>AED '000'</b>	<b>AED '000'</b>
Profit for the period	47,624	32,297	24,416	15,592
Other comprehensive income :				
<i>Items that will not be reclassified subsequently to profit or loss:</i>				
Gain on sale of investments at FVTOCI	2,218	--	317	--
(Decrease)/increase in fair value of investments at FVTOCI	(6,032)	14,163	(5,513)	20,433
Net other comprehensive (loss)/income	(3,814)	14,163	(5,196)	20,433
<b>Total comprehensive income for the period – Exhibit C</b>	<b>43,810</b>	<b>46,460</b>	<b>19,220</b>	<b>36,025</b>
Attributable to :				
Equity holders of the parent company	32,800	41,606	14,590	34,661
Non-controlling interest	11,010	4,854	4,630	1,364
<b>Total Amount</b>	<b>43,810</b>	<b>46,460</b>	<b>19,220</b>	<b>36,025</b>

THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE  
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Condensed consolidated interim statement of changes in equity  
For the six months period ended 30 June 2024 (Unaudited)

EXHIBIT C

## **Attributable to equity holders of the parent company**

	Share capital AED '000'	Reserves AED '000'	Cumulative change in fair value of investments at - FVTOCI AED '000'	Retained earnings AED '000'	Total AED '000'	Non-controlling interest AED '000'	Total AED '000'
Balance at 1 January 2023 (Audited)	698,916	292,453	(98,271)	178,343	1,071,441	53,452	1,124,893
Profit for the six months period ended 30 June 2023 - Exhibit B	--	--	--	27,443	27,443	4,854	32,297
Other comprehensive income	--	--	14,163	--	14,163	--	14,163
Total comprehensive income (Unaudited)	--	--	14,163	27,443	41,606	4,854	46,460
Cash dividends	--	--	--	(69,892)	(69,892)	--	(69,892)
Board of directors remuneration	--	--	--	(3,200)	(3,200)	--	(3,200)
Balance at 30 June 2023 (Unaudited)	698,916	292,453	(84,108)	132,694	1,039,955	58,306	1,098,261
Balance at 1 January 2024 (Audited)	698,916	298,434	(49,163)	159,078	1,107,265	68,870	1,176,135
Profit for the six months period ended 30 June 2024 - Exhibit B	--	--	--	36,614	36,614	11,010	47,624
Other comprehensive loss	--	--	(6,032)	2,218	(3,814)	--	(3,814)
Total comprehensive income (Unaudited)	--	--	(6,032)	38,832	32,800	11,010	43,810
Cash dividends	--	--	--	(69,892)	(69,892)	--	(69,892)
Board of directors remuneration	--	--	--	(5,382)	(5,382)	--	(5,382)
Transfer of fair value reserve on disposal of investments at FVTOCI	--	--	9,461	(9,461)	--	--	--
Balance at 30 June 2024 (Unaudited) - Exhibit A	698,916	298,434	(45,734)	113,175	1,064,791	79,880	1,144,671

THE ACCOMPANYING NOTES CONSTITUTE AN  
INTEGRAL PART OF THESE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

**GULF MEDICAL PROJECTS COMPANY (PJSC)**  
Condensed consolidated interim statement of cash flows  
For the six months period ended 30 June 2024 (Unaudited)

**EXHIBIT D**

	<u>Six months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>AED '000'</u>	<u>AED '000'</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit for the period – <b>Exhibit B</b>	47,624	32,297
<b>Adjustments for:</b>		
Depreciation of property and equipment	12,617	12,251
Depreciation of right-of-use assets	1,218	1,231
Amortization of intangible assets	259	244
Dividends income	(13,756)	(11,257)
Fair value loss/(gain) on revaluation of investments at FVTPL	3,710	(2,679)
Loss/(profit) from a related party	199	(33)
Provision for impairment loss of accounts receivable	14,453	11,146
Loss/(gain) on sale of property and equipment	445	(2)
Employees end of service benefits	2,409	3,046
Income tax expenses	3,734	--
Finance costs – lease liabilities	85	109
Interest income	(1,971)	(1,070)
Operating cash flows before changes in operating assets and liabilities	71,026	45,283
(Increase)/decrease in inventories	(1,827)	710
Increase in due from a related party	(87)	(159)
Increase in accounts receivable and others	(40,184)	(24,065)
(Decrease)/increase in accounts payable and others	(2,399)	8,402
Settlements of employees end of service benefits	(1,616)	(1,522)
<b>Net Cash Provided by Operating Activities</b>	<b>24,913</b>	<b>28,649</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
(Increase)/decrease in fixed deposits	(29,107)	20,477
Interest income received	1,704	1,206
Purchase of property and equipment	(10,784)	(4,422)
Purchase of intangible assets	(303)	(175)
Proceeds from sale of property and equipment	1	3
Proceed from sale of investments at FVTOCI	51,155	--
Dividends received	13,756	11,257
<b>Net Cash Provided by Investing Activities</b>	<b>26,422</b>	<b>28,346</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Repayment of lease liabilities	(435)	(1,735)
Cash dividends paid	(69,892)	(69,892)
Board of directors remuneration paid	(5,382)	(3,200)
<b>Net Cash Used in Financing Activities</b>	<b>(75,709)</b>	<b>(74,827)</b>
<b>Net decrease in cash and cash equivalents</b>	<b>(24,374)</b>	<b>(17,832)</b>
Cash and cash equivalents at beginning of period	48,857	44,371
<b>Cash and Cash Equivalents at end of Period - Note 23</b>	<b>24,483</b>	<b>26,539</b>

**THE ACCOMPANYING NOTES CONSTITUTE AN INTEGRAL PART OF THESE  
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS**



## **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

---

### **1. STATUS AND ACTIVITIES**

**Gulf Medical Projects Company – Sharjah** (hereinafter referred to as the “**Company**”) is a public shareholding company incorporated in Sharjah by an Amiri Decree No. 48/79 issued by His Highness The Ruler of Sharjah on 2 August 1979.

The main activities of the Company and its subsidiary (together referred to as the “**Group**”) are general hospital, telehealth services and home health care center, advanced first aid training center, hospitals management and establishment of medicine manufacturing factories.

The Company is domiciled in Sharjah city and its registered address is P.O. Box: 5385, Sharjah, United Arab Emirates.

### **2. BASIS OF PREPARATION**

#### **2.1 Statement of compliance**

The condensed consolidated interim financial statements for the six months period ended 30 June 2024 have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting”.

Condensed consolidated interim financial statements does not include all of the information and footnotes required for full annual consolidated financial statements prepared in accordance with International Financial Reporting Standards and should be read in conjunction with the Group’s annual consolidated audited financial statements as at and for the year ended 31 December 2023. In addition, results for the six months period ended 30 June 2024 for the Group are not necessarily indicative of the results that may be expected for the financial year ended 31 December 2024.

#### **2.2 Basis of measurement**

These condensed consolidated interim financial statements have been prepared on the historical cost basis except for investment properties, land and investment in financial assets which have been measured on the basis of fair value/valuation.

#### **2.3 Functional and Presentation Currency**

These condensed consolidated interim financial statements are presented in UAE Dirham (AED), which is the Group’s Functional Currency. Amounts in the condensed consolidated interim financial statements are rounded to the nearest Thousand Arab Emirates Dirham (AED ‘000’).

#### **2.4 Use of estimates, assumptions and judgments**

The preparation of these condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that effect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

## **GULF MEDICAL PROJECTS COMPANY (PJSC)**

### **Notes to the condensed consolidated interim financial statements**

**For the six months period ended 30 June 2024**

---

#### **2. BASIS OF PREPARATION (CONTINUED)**

##### **2.4 Use of estimates, assumptions and judgments (Continued)**

In preparing these condensed consolidated interim financial statements the significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as that were applied to consolidated financial statements for the year ended 31 December 2023.

##### **2.5 Income tax expense**

Income tax expense is recognised during the six months period ended 30 June 2024 based on management's estimate of the weighted-average effective annual income tax rate expected for the full financial year.

Amounts accrued for tax expense in an interim period may have to be adjusted in subsequent interim periods if the estimate of the annual income tax rate changes.

##### **2.6 Financial risk management**

The Group's financial risk management objective and policies are consistent with those disclosed in audited consolidated financial statements for the year ended 31 December 2023.

##### **2.7 Basis of consolidation**

These condensed consolidated interim financial statements incorporate the condensed interim financial statements of the parent company and entity controlled by the Company (its subsidiary). Control is achieved when the Group has :

- The Group has power over the investee.
- The Group is exposed, or has rights, to variable returns from its involvement with the investee.
- The Group has the ability to use its power over the investee to affect its returns.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control mentioned above.

When the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts circumstances whether it has power over an investee, including:

- The contractual arrangement with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed during the period is included in the condensed consolidated interim statement of income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

Profit or loss and each component of other comprehensive income are attributable to the equity holders of the parent company and to the non-controlling interest even if this results in the non-controlling interest having a deficit balance.

## **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

---

### **2. BASIS OF PREPARATION (CONTINUED)**

#### **2.7 Basis of consolidation (Continued)**

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group accounting policies.

All intragroup balances and income, equity and cash flows relating to transactions between entities of the Group are eliminated in full on consolidation.

Changes in the Group ownership interests in subsidiaries that do not result in the Group losing control over subsidiaries are accounted for as equity transactions. The carrying amounts of the Group interests and the non-controlling interest are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interest are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to owners of the Group.

The details of the subsidiary is as follows :

<u>Company</u>	<u>% of ownership</u>		<u>Principal activities</u>	<u>Country of incorporation</u>
	<u>30 June 2024</u>	<u>31 December 2023</u>		
Al Zahra (Pvt.) Hospital Dubai (L.L.C)	68.38	68.38	General Hospital, home healthcare center and telehealth services and advance first aid training center.	UAE

### **3. MATERIAL ACCOUNTING POLICY INFORMATION**

The accounting policies used in the preparation of these condensed consolidated interim financial statements are consistent with those used in the Group's audited annual consolidated financial statements for the year ended 31 December 2023.

The new revised relevant IFRSs effective from 1 January 2024 had no material impact on the condensed consolidated interim financial position or performance of the Group during the period.

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements  
For the six months period ended 30 June 2024

## **4. PROPERTY AND EQUIPMENT**

a) The details of this item are as follows :

	Land AED '000'	Hospital buildings AED '000'	Hospital furniture and equipment AED '000'	Motor vehicles AED '000'	Other furniture and equipment AED '000'	Capital work- in-progress AED '000'	Total AED '000'
<b>Cost/Revaluation :</b>							
At 1 January 2023	250,482	576,808	139,743	4,759	16,747	496	989,035
Additions during the year	--	2,040	11,715	739	178	748	15,420
Disposals during the year	--	(216)	(326)	(832)	(102)	--	(1,476)
Transfer	--	--	496	--	--	(496)	--
<b>At 31 December 2023</b>	<b>250,482</b>	<b>578,632</b>	<b>151,628</b>	<b>4,666</b>	<b>16,823</b>	<b>748</b>	<b>1,002,979</b>
Additions during the period	--	890	6,711	--	261	2,922	10,784
Disposals during the period	--	--	(1,089)	--	(68)	--	(1,157)
Transfer	--	2,346	--	--	--	(2,346)	--
<b>Balance at 30 June 2024</b>	<b>250,482</b>	<b>581,868</b>	<b>157,250</b>	<b>4,666</b>	<b>17,016</b>	<b>1,324</b>	<b>1,012,606</b>
<b>Accumulated Depreciation :</b>							
At 1 January 2023	--	144,121	114,862	3,871	15,220	--	278,074
Charged for the year	--	15,933	7,478	312	757	--	24,480
Relating to disposals	--	(216)	(325)	(832)	(102)	--	(1,475)
<b>At 31 December 2023</b>	<b>--</b>	<b>159,838</b>	<b>122,015</b>	<b>3,351</b>	<b>15,875</b>	<b>--</b>	<b>301,079</b>
Charged for the period	--	8,014	4,132	170	301	--	12,617
Relating to disposals	--	--	(643)	--	(68)	--	(711)
<b>Balance at 30 June 2024</b>	<b>--</b>	<b>167,852</b>	<b>125,504</b>	<b>3,521</b>	<b>16,108</b>	<b>--</b>	<b>312,985</b>
<b>Net Book Value</b>							
At 30 June 2024 - Exhibit A (Unaudited)	250,482	414,016	31,746	1,145	908	1,324	699,621
At 31 December 2023 - Exhibit A (Audited)	250,482	418,794	29,613	1,315	948	748	701,900

**GULF MEDICAL PROJECTS COMPANY (PJSC)****Notes to the condensed consolidated interim financial statements**

For the six months period ended 30 June 2024

**4. PROPERTY AND EQUIPMENT (CONTINUED)**

- b) Land of AED. 250,482 thousand mentioned above represents the fair value of a plot of land at date of acquisition measuring 350,000 square feet registered with the concerned government department in the name of the subsidiary.
- c) Capital work-in-progress of AED. 1,324 thousand mentioned above represent the costs incurred for the modification work at the dialysis unit, acoustic movable walls system and heat pumps and accessories at the Hospital in the Emirate of Dubai.
- d) Depreciation for the period is allocated to cost of revenues and general and administrative expenses amounting to AED. 12,425 thousand (At 30 June 2023 : AED. 12,041 thousand) and AED. 192 thousand (At 30 June 2023 : AED. 210 thousand), respectively.

**5. INTANGIBLE ASSETS**

- a) This item consists of the following :

	<b>Software AED '000'</b>
<b>Cost</b>	
At 1 January 2023	3,457
Additions	175
<b>At 31 December 2023</b>	<b>3,632</b>
Additions	303
<b>Balance at 30 June 2024</b>	<b>3,935</b>
<b>Accumulated Amortization</b>	
At 1 January 2023	2,170
Charged for the year	502
<b>At 31 December 2023</b>	<b>2,672</b>
Charged for the period	259
<b>Balance at 30 June 2024</b>	<b>2,931</b>
<b>Net book Value</b>	
At 30 June 2024 – Exhibit A (Unaudited)	1,004
At 31 December 2023 – Exhibit A (Audited)	960

- b) Amortization for the period is allocated to cost of revenues and general administrative expenses amounting to AED. 258 thousand (At 30 June 2023 : AED. 243 thousand) and AED. 1 thousand (At 30 June 2023 : AED. 1 thousand) respectively.

**6. RIGHT-OF-USE ASSETS**

The movement of right-of-use assets are summarized as follows :

	<b>30 June 2024 (Unaudited) AED '000'</b>	<b>31 December 2023 (Audited) AED '000'</b>
At 1 January	9,789	10,534
Addition during the period/year	--	1,707
Charged for the period/year	(1,218)	(2,452)
<b>Net balance at the end of the period/year – Exhibit A</b>	<b>8,571</b>	<b>9,789</b>

## GULF MEDICAL PROJECTS COMPANY (PJSC)

### Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

#### 7. INVESTMENT PROPERTIES

a) This item consists of the following :

	<b>30 June 2024</b> <b>(Unaudited)</b> <b>AED '000'</b>	<b>31 December 2023</b> <b>(Audited)</b> <b>AED '000'</b>
Fair value at 1 January	91,091	85,105
Increase in fair value	--	5,986
<b>Fair Value at end of the period/year – Exhibit A</b>	<b>91,091</b>	<b>91,091</b>

b) Investment properties of AED. 91,091 thousand mentioned above represent the fair value at the review report date as per management estimate.

c) Investment properties represent investments in land and real estates in the United Arab Emirates.

#### 8. INVESTMENTS IN FINANCIAL ASSETS

Investments in financial assets comprise of the following :

a) **Investments at fair value through other comprehensive income (FVTOCI)**

This item consists of the following :

	<b>30 June 2024</b> <b>(Unaudited)</b> <b>AED '000'</b>	<b>31 December 2023</b> <b>(Audited)</b> <b>AED '000'</b>
Fair value at 1 January	259,053	209,945
Sales during the period/year	(51,155)	--
Gain on sale of investments at FVTOCI	2,218	--
(Decrease)/increase in fair value	(6,032)	49,108
<b>Fair value at end of the period/year – Exhibit A</b>	<b>204,084</b>	<b>259,053</b>

Investments at fair value through other comprehensive income represent investments in securities quoted in the local financial markets.

b) **Investments at fair value through profit or loss (FVTPL)**

This item consists of the following :

	<b>30 June 2024</b> <b>(Unaudited)</b> <b>AED '000'</b>	<b>31 December 2023</b> <b>(Audited)</b> <b>AED '000'</b>
Fair value at 1 January	39,406	36,748
(Decrease)/increase in fair value	(3,710)	2,658
<b>Fair Value at end of the period/year - Exhibit A</b>	<b>35,696</b>	<b>39,406</b>

Investments at fair value through profit or loss represent investment in securities quoted in local and regional financial markets.

**GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

**9. INVENTORIES**

This item consists of the following :

	<b>30 June 2024</b>	<b>31 December 2023</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Goods for sale (drugs and cosmetics)	9,162	7,893
General stores and hospital supplies	8,415	7,857
Provision for slow-moving items	(590)	(590)
<b>Net Amount – Exhibit A</b>	<b>16,987</b>	<b>15,160</b>

**10. BALANCES AND TRANSACTIONS WITH RELATED PARTIES**

In the normal course of business, the Group enters into various transactions with related parties. Related parties represent major shareholders, directors and key management personnel of the group, and entities controlled, jointly controlled or significantly influenced by such parties. The prices and terms of these transactions are agreed with the Group's management.

- Due from a related party**

This item represents the amount due from Gulf Medical Commercial Agencies (LLC) – Sharjah. As per the management contract the Company is managed and financed by the Group in return for obtaining all the profit/(losses) generated by the Company which has been included in the condensed consolidated interim statement of income for the Group. The details of the movement in this account are as follows :

	<b>30 June 2024</b>	<b>31 December 2023</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Balance at 1 January	2,193	2,258
Net funds received/(paid)	87	(26)
Loss for the period/year transferred	(199)	(39)
<b>Balance at end of the period/year – Exhibit A</b>	<b>2,081</b>	<b>2,193</b>

- The following are the details of significant related parties transactions :

	<b>Six months period ended</b>	
	<b>30 June 2024</b>	<b>30 June 2023</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Purchases	372	532
Expenses	265	273

**GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

**10. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (CONTINUED)**

- The remuneration, salaries and other benefits of Board of Directors and other members of key management during the period are as follows :

	<u>Six months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'
Board of directors remuneration (as approved by the Annual General Meeting)	5,382	3,200
Key management salaries and other related benefits	4,953	3,893
Board committee expenses	173	79

**11. ACCOUNTS RECEIVABLE AND OTHERS**

- a) This item consists of the following :

	<u>30 June 2024</u>	<u>31 December 2023</u>
	<u>(Unaudited)</u>	<u>(Audited)</u>
	AED '000'	AED '000'
Accounts receivable	230,149	199,873
Provision for impairment loss of accounts receivable – Note 11(b)	(104,752)	(92,840)
Net Amount	125,397	107,033
Prepaid expenses	10,187	4,663
Recoverable tax	2,296	822
Post-dated cheques received	403	432
Refundable deposits	1,215	1,215
Interest receivable	658	391
Staff receivables	411	170
Margin held with banks	1,008	1,019
Advance payment	2,059	1,736
Due from a local brokerage company	–	160
Others	10	5
<b>Total - Exhibit A</b>	<b>143,644</b>	<b>117,646</b>

- b) The details of movement in provision for impairment loss of accounts receivable are as follows:

	<u>30 June 2024</u>	<u>31 December 2023</u>
	<u>(Unaudited)</u>	<u>(Audited)</u>
	AED '000'	AED '000'
Balance at 1 January	92,840	105,057
Addition during the period/year	14,453	22,492
Written off during the period/year	(2,541)	(34,709)
<b>Balance at the end of the period/year – Note 11(a)</b>	<b>104,752</b>	<b>92,840</b>



**GULF MEDICAL PROJECTS COMPANY (PJSC)****Notes to the condensed consolidated interim financial statements**

For the six months period ended 30 June 2024

**12. CASH AND BANK BALANCES**

This item consists of the following :

	<u><b>30 June 2024</b></u> <u><b>(Unaudited)</b></u> <b>AED '000'</b>	<u><b>31 December 2023</b></u> <u><b>(Audited)</b></u> <b>AED '000'</b>
Cash in hand	251	248
Bank balances - Current and call deposit accounts	24,232	48,609
Fixed deposits	103,035	73,928
<b>Total - Exhibit A</b>	<u><u><b>127,518</b></u></u>	<u><u><b>122,785</b></u></u>

**13. SHARE CAPITAL**

This item consists of the following :

	<u><b>30 June 2024</b></u> <u><b>(Unaudited)</b></u> <b>AED '000'</b>	<u><b>31 December 2023</b></u> <u><b>(Audited)</b></u> <b>AED '000'</b>
<b>Authorized share capital is 698,916,094 ordinary shares of AED. 1 each fully paid – Exhibit A</b>	<u><u><b>698,916</b></u></u>	<u><u><b>698,916</b></u></u>

**14. NON-CONTROLLING INTEREST**

a) The details of movement in this item during the period/year are as follows :

	<u><b>30 June 2024</b></u> <u><b>(Unaudited)</b></u> <b>AED '000'</b>	<u><b>31 December 2023</b></u> <u><b>(Audited)</b></u> <b>AED '000'</b>
Balance at 1 January	68,870	53,452
Share of profit for the period/year	11,010	15,418
<b>Balance at end of the period/year - Exhibit A</b>	<u><u><b>79,880</b></u></u>	<u><u><b>68,870</b></u></u>

b) Non-controlling interest mentioned above represents the share of non-controlling as at the condensed consolidated interim statement of financial position date and are as follows:

	<u><b>30 June 2024</b></u> <u><b>(Unaudited)</b></u> <b>%</b>	<u><b>31 December 2023</b></u> <u><b>(Audited)</b></u> <b>%</b>
Share in Al Zahra (Pvt) Hospital Dubai (L.L.C)	<u><u><b>31.62</b></u></u>	<u><u><b>31.62</b></u></u>

**15. EMPLOYEES' END OF SERVICE BENEFITS**

The details of movement in this item during the period/year are as follows:

	<u><b>30 June 2024</b></u> <u><b>(Unaudited)</b></u> <b>AED '000'</b>	<u><b>31 December 2023</b></u> <u><b>(Audited)</b></u> <b>AED '000'</b>
Balance at 1 January	25,027	22,953
Current service cost	2,409	5,815
Settlements	(1,616)	(3,741)
<b>Balance at end of the period/year – Exhibit A</b>	<u><u><b>25,820</b></u></u>	<u><u><b>25,027</b></u></u>

**GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

**16. LEASE LIABILITIES**

Lease liabilities represent the long term leases of staff accommodation and robotics surgical systems up to the year 2029. The details of movement in this item during the period/year are as follows :

	<b>30 June 2024</b>	<b>31 December 2023</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Balance at 1 January	8,115	9,856
Additions during the period/year	--	1,707
Interest on lease liabilities for the period/year	85	198
Payments during the period/year	(435)	(3,646)
<b>Balance at the end of the period/year</b>	<b>7,765</b>	<b>8,115</b>
<b>Non-Current – Exhibit A</b>	<b>4,566</b>	<b>5,870</b>
<b>Current – Exhibit A</b>	<b>3,199</b>	<b>2,245</b>
<b>Total</b>	<b>7,765</b>	<b>8,115</b>

**17. ACCOUNTS PAYABLE AND OTHERS**

This item consists of the following :

	<b>30 June 2024</b>	<b>31 December 2023</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Accounts payable	53,246	56,356
Uncollected portion of repayments to shareholders	1,070	1,070
Post -dated cheques issued	11,434	14,167
Accrued expenses	9,837	7,834
Provision for staff leave salaries and air passage	16,428	12,928
Income received in advance	1,262	908
Staff payables	158	359
Shareholder's dividend payable – Kuwait Nationals	--	6,346
Others	54,872	50,738
<b>Total - Exhibit A</b>	<b>148,307</b>	<b>150,706</b>

**18. SEGMENT INFORMATION**

The Board of Directors are chief operating decision makers. Management determine the operation segments based on segments identified for the purpose of allocation resources and assessing performance.

The Group's reportable segments are organized into two major segments as follows:

- i) Health services and others      Principally providing health, medical care and other related services.
- ii) Investments                      Principally concerned with investment properties and investment in securities.

Performance of each segment is measured based on segment profit as management believes that profit is the most relevant factor in evaluating the results of segment.

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements  
For the six months period ended 30 June 2024

## **18. SEGMENT INFORMATION (CONTINUED)**

The financial analysis according to the business segments are as follows :

	<b>Health Services &amp; others</b>		<b>Investments</b>		<b>Total</b>
	<b>Six months period ended</b>	<b>30 June 2023</b>	<b>Six months period ended</b>	<b>30 June 2023</b>	<b>Six months period ended</b>
	<b>30 June 2024</b>	<b>(Unaudited)</b>	<b>30 June 2024</b>	<b>(Unaudited)</b>	<b>30 June 2024</b>
	<b>AED '000'</b>	<b>AED '000'</b>	<b>AED '000'</b>	<b>AED '000'</b>	<b>(Unaudited)</b>
					<b>AED '000'</b>
<b>Revenues</b>					
Total revenues	331,210	268,925	12,501	15,307	343,711
					284,232
<b>Result</b>					
Segment result	91,192	60,926	12,351	15,211	103,543
					76,137
Unallocated general and administrative expenses					(56,044)
					(47,446)
Operating profit					47,499
Other income	3,859	3,606	--	--	3,859
					28,691
Profit from operation before tax					51,358
Income tax expenses					(3,734)
					32,297
Profit from operation					47,624
Attributable to non-controlling interest					(11,010)
					32,297
Profit for the period					36,614
					27,443

# **GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements  
For the six months period ended 30 June 2024

## **18. SEGMENT INFORMATION (CONTINUED)**

	<u>Health Services &amp; others</u>		<u>Investments</u>		<u>Total</u>	
	<u>30 June 2024</u> <u>(Unaudited)</u> <u>AED '000'</u>	<u>31 December 2023</u> <u>(Audited)</u> <u>AED '000'</u>	<u>30 June 2024</u> <u>(Unaudited)</u> <u>AED '000'</u>	<u>31 December 2023</u> <u>(Audited)</u> <u>AED '000'</u>	<u>30 June 2024</u> <u>(Unaudited)</u> <u>AED '000'</u>	<u>31 December 2023</u> <u>(Audited)</u> <u>AED '000'</u>
<b>Other information</b>						
Segment assets	877,815	885,647	452,482	474,336	1,330,297	1,359,983
Segment liabilities	180,322	173,278	4,804	10,570	185,626	183,848
Capital expenditure	11,087	15,595	--	--	11,087	15,595

## GULF MEDICAL PROJECTS COMPANY (PJSC)

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

### 19. REVENUES

a) This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'	AED '000'	AED '000'
Revenue from contracts with customers - Exhibit B	<u>331,210</u>	<u>268,925</u>	<u>164,159</u>	<u>132,973</u>

### b) Disaggregation of revenue from contracts with customers

Set out below is the disaggregation of the Group's revenue from contracts with customers :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	AED '000'	AED '000'	AED '000'	AED '000'
<b>Segments</b>				
<b>Type of services</b>				
Revenue from healthcare services	<u>331,210</u>	<u>268,925</u>	<u>164,159</u>	<u>132,973</u>
<b>Geographical markets</b>				
Revenue within UAE	<u>331,210</u>	<u>268,925</u>	<u>164,159</u>	<u>132,973</u>
<b>Timing of revenue recognition</b>				
Services and goods transferred at a point in time	<u>331,210</u>	<u>268,925</u>	<u>164,159</u>	<u>132,973</u>

### c) Performance obligations

Information about the Group's performance obligations are summarized below :

#### Rendering of services

Health care services revenues primarily comprise fees charged for inpatient and outpatient medical services. Services include charges for accommodation, theatre, medical professional services, equipment, laboratory and pharmaceutical items used and recorded at the time of billing.

#### Sale of goods

Revenue from sale of goods represent the total revenue from sale of drug and cosmetics provided to customers and is recognized when control and benefits are transferred and billed.

**GULF MEDICAL PROJECTS COMPANY (PJSC)****Notes to the condensed consolidated interim financial statements**

For the six months period ended 30 June 2024

**20. COST OF REVENUES**

This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>
Salaries and other related benefits	142,576	122,855	71,572	62,330
Supplies and services	83,541	71,629	42,515	36,673
Depreciation of property and equipment	12,425	12,041	6,311	6,013
Depreciation of right-of-use assets	1,218	1,231	609	609
Amortization of intangible assets	258	243	139	128
<b>Total - Exhibit B</b>	<b>240,018</b>	<b>207,999</b>	<b>121,146</b>	<b>105,753</b>

**21. GENERAL AND ADMINISTRATIVE EXPENSES**

This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>	<u>AED '000'</u>
Staff salaries and other related benefits	27,244	22,131	13,663	11,131
Board committee expenses	173	79	51	37
Electricity and water	3,235	3,125	1,795	1,718
Advertising and publicity	1,347	1,096	744	438
Provision for impairment loss of accounts receivable	14,453	11,146	7,572	5,541
Government expenses	3,130	3,036	1,376	1,285
Telephone and postage	413	410	206	210
Insurance	742	751	371	382
Donation and charity	700	750	700	750
Legal and professional fees	1,496	1,755	781	1,056
Banks and credit card charges	1,055	880	488	425
Depreciation of property and equipment	192	210	96	82
Amortization of intangible assets	1	1	--	--
Miscellaneous expenses	1,778	1,967	897	1,075
<b>Total - Exhibit B</b>	<b>55,959</b>	<b>47,337</b>	<b>28,740</b>	<b>24,130</b>

**22. BASIC EARNINGS PER SHARE**

This item consists of the following :

	<u>Six months period ended</u>		<u>Three months period ended</u>	
	<u>30 June 2024</u>	<u>30 June 2023</u>	<u>30 June 2024</u>	<u>30 June 2023</u>
	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>	<u>(Unaudited)</u>
Profit for the period attributable to equity holders of the Parent Company (AED '000')	36,614	27,443	19,786	14,228
Weighted average number of shares (Share '000')	698,916	698,916	698,916	698,916
<b>Basic earnings per share (AED) - Exhibit B</b>	<b>0.052</b>	<b>0.039</b>	<b>0.028</b>	<b>0.020</b>

## GULF MEDICAL PROJECTS COMPANY (PJSC)

### Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

#### 23. CASH AND CASH EQUIVALENTS

At 30 June 2024 and 2023 “cash and cash equivalents” included in the condensed consolidated interim statement of cash flows (Exhibit D) comprise the following items :

	<b>Six months period ended</b>	
	<b>30 June 2024</b>	<b>30 June 2023</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Cash in hand	251	416
Bank balances – Current and call accounts	24,232	26,123
<b>Total - Exhibit D</b>	<b>24,483</b>	<b>26,539</b>

#### 24. DIVIDEND AND DIRECTORS' REMUNERATION

- At the Annual General Meeting held on 7 March 2024, the shareholders approved 10% cash dividend proposed by the Board of Directors.
- At the Annual General Meeting held on 7 March 2024, the shareholders approved the proposed Board of Directors' remuneration amounting to AED. 5,382 thousand for the year ended 31 December 2023.

#### 25. CONTINGENT LIABILITIES/COMMITMENTS

##### i) *Contingent liabilities*

Contingent liabilities of the Group as at the condensed consolidated interim statement of financial position date amounted to AED. 1,008 thousand (Unaudited) [(31 December 2023: AED. 1,019 thousand) (Audited)] representing guarantees issued.

##### ii) *Commitments*

Commitments of the group as at the condensed consolidated interim statement of financial position date are as follows :

	<b>30 June 2024</b>	<b>31 December 2023</b>
	<b>(Unaudited)</b>	<b>(Audited)</b>
	<b>AED '000'</b>	<b>AED '000'</b>
Capital purchases	9,600	9,355

#### 26. INCOME TAX EXPENSE

##### *Corporate Tax Law*

On 9 December 2022, the UAE Ministry of Finance released Federal Decree-Law No. 47 of 2022 on the Taxation of Corporations and Businesses, Corporate Tax Law (“CT Law”) to enact a Federal corporate tax regime in the UAE. Furthermore, a Cabinet Decision was published which specifies that taxable income not exceeding AED. 375,000 would be subject to a 0% UAE CT rate and taxable income exceeding AED. 375,000 would be subject to the 9% UAE CT rate.

As the Group’s accounting year ends on 31 December, accordingly the effective implementation date for the Group will start from 1 January 2024 to 31 December 2024, with the first return to be filed on or before 30 September 2025.

**GULF MEDICAL PROJECTS COMPANY (PJSC)**

Notes to the condensed consolidated interim financial statements

For the six months period ended 30 June 2024

---

**26. INCOME TAX EXPENSE (CONTINUED)**

The income tax expense for period ended 30 June 2024 is AED. 3,734 thousand (30 June 2023: AED Nil thousand).

**27. COMPARATIVE FIGURES**

Certain comparative figures have been reclassified to comply with those of current period presentation.